恩替卡韦联合聚乙二醇干扰素治疗慢性乙型肝炎患者疗效观察

doi:10.3969/j.issn.1672-5069.2016.02.021

Abstract

Chen Yaping, Zhang Qinjian, Tian Nannan. Clinical efficacy of entecavir combined with pegylated interferon-α in the treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 208-209.

References

[1] Yao JY,Chao K,Li MR,et al. Interleukin-21 gene polymorphisms and chronic hepatitis B infection in a Chinese population. World J Gastroenterol,2015,21（14）:4232-4239.
[2] 李菊兰,苏智军,余雪平. 慢性乙型肝炎患者血清甲状腺相关物质和IL-6检测及其临床意义. 实用肝脏病杂志,2014,17（1）:48-50.
[3] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南（2010年版）.实用肝脏病杂志,2011,14（2）:81-89.
[4] Yeh ML,Peng CY,Dai CY,et al. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.PLoS One,2015,10（4）:e0122259.
[5] Bier K,Ari A,Gen VE,et al. Efficacy of entecavir treatment among chronic hepatitis B nucleos（t）ide-nave and -experienced patients. Turk J Med Sci,2015,45（1）:99-104.
[6] Yang C,Ruan P,Ou C,et al.Chronic hepatitis B virus infection and occurrence of hepatocellular carcinoma in tree shrews （Tupaia belangeri chinensis）.Virol J,2015,12（1）:26.
[7] 李彩东,杨勇卫,田鹏飞,等.慢性乙型肝炎病毒感染者血清MIF、IL-17和IL-10水平变化.实用肝脏病杂志,2015,18（1）:71-73.
[8] Yuen MF,Ahn SH,Lee KS,et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir:results from a multicentre study. J Hepatol,2015,62（3）:526-532.
[9] Guclu E,Tuna N,Karabay O,et al. Predictors of response to pegylated interferon treatment in HBeAg-negative patients with chronic hepatitis B. J Infect Dev Ctries,2014,8（12）:1601-1608.
[10] Dogan UB,Golge N,Akin MS. The comparison of the efficacy ofpegylated interferon-2a and α-2b in chronic hepatitis B patients.Eur J Gastroenterol Hepatol,2013,25（11）:1312-1316.
[11] Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol,2014,20（23）:7169-7180.
[12] Seto WK,Hui AJ,Wong VW,et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study.Gut,2015,64（4）:667-672.
[13] Xie Q,Zhou H,Bai X,et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a（40KD）andentecavir treatment for hepatitis B“e”antigen-positivechronic hepatitis B. Clin Infect Dis,2014,59（12）:1714-1723.
[14] Brouwer WP,Xie Q,Sonneveld MJ,et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive?chronic hepatitis B:A multicenter randomized trial （ARES study）.Hepatology,2015,61（5）:1512-1522.

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[7]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[8]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[9]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[10]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[11]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[12]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[13]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[14]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[15]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.

Clinical efficacy of entecavir combined with pegylated interferon-α in the treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments